Issue Date: October 31, 2011
Biogen And Portola Target Arthritis
Biogen Idec and Portola Pharmaceuticals will collaborate to develop Portola’s small-molecule Syk inhibitors for the treatment of autoimmune and inflammatory diseases including rheumatoid arthritis. Biogen will provide Portola with $45 million up front and could make additional payments of up to $509 million. The collaboration’s lead molecule, PRT062607, is in Phase I studies. Biogen Idec’s product line today consists entirely of biologic drugs.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society